Literature DB >> 1568771

Hepatosplenic schistosomiasis. Pathophysiology and treatment.

L C Da Silva1, F J Carrilho.   

Abstract

HSS represents a special model of intrahepatic portal hypertension characterized by a presinusoidal portal block and a well-preserved liver parenchyma. Symmers' fibrosis appears in a small but significant proportion of patients with a high worm load. Its pathogenesis is not well established, although experimental and clinical studies point to egg granulomata as the main pathogenetic factor. The eggs carried continuously through the portal circulation produce inflammation and gross amputation of the intrahepatic veins, portal and periportal granulomas, and, eventually, a coarse perilobular fibrosis ("pipe-stem"). Portal hypertension, esophageal varices, and hepatosplenomegaly are the main consequences of these morphologic changes. Gastrointestinal bleeding is the most frequent cause of death. Unlike in cirrhosis, advanced liver failure is not seen except when HSS is associated with liver lesions from other causes such as virus and alcoholism. Helminthiasis treatment is based on chemotherapy with praziquantel or oxamniquine. Bleeding esophageal varices are managed by sclerotherapy or surgical procedures. Splenectomy with gastroesophageal devascularization seems to be the best choice.

Entities:  

Mesh:

Year:  1992        PMID: 1568771

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  12 in total

1.  Long-term results of esophagogastric devascularization and splenectomy associated with endoscopic treatment in schistosomal portal hypertension.

Authors:  Fabio Ferrari Makdissi; Paulo Herman; Vincenzo Pugliese; Roberto de Cleva; William Abrão Saad; Ivan Cecconello; Luiz Augusto Carneiro D'Albuquerque
Journal:  World J Surg       Date:  2010-11       Impact factor: 3.352

Review 2.  Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective.

Authors:  Brian B Graham; Angela Pontes Bandeira; Nicholas W Morrell; Ghazwan Butrous; Rubin M Tuder
Journal:  Chest       Date:  2010-06       Impact factor: 9.410

Review 3.  Schistosomiasis and the pulmonary vasculature (2013 Grover Conference series).

Authors:  Brian B Graham; Rahul Kumar
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

4.  Peliosis hepatis as an early histological finding in idiopathic portal hypertension: A case report.

Authors:  Annalisa Berzigotti; Donatella Magalotti; Paola Zappoli; Cristina Rossi; Francesco Callea; Marco Zoli
Journal:  World J Gastroenterol       Date:  2006-06-14       Impact factor: 5.742

Review 5.  Hypogenesis of right hepatic lobe accompanied by portal hypertension: case report and review of 31 Japanese cases.

Authors:  T Inoue; Y Ito; Y Matsuzaki; Y Okauchi; H Kondo; N Horiuchi; K Nakao; M Iwata
Journal:  J Gastroenterol       Date:  1997-12       Impact factor: 7.527

6.  Variceal pressure is a strong predictor of variceal haemorrhage in patients with cirrhosis as well as in patients with non-cirrhotic portal hypertension.

Authors:  E A El Atti; F Nevens; K Bogaerts; G Verbeke; J Fevery
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

7.  Surgical portosystemic shunts versus devascularisation procedures for prevention of variceal rebleeding in people with hepatosplenic schistosomiasis.

Authors:  Chikwendu J Ede; Dimitrinka Nikolova; Martin Brand
Journal:  Cochrane Database Syst Rev       Date:  2018-08-03

Review 8.  Relation between liver pathology and prognosis in patients with portal hypertension.

Authors:  P A McCormick; A K Burroughs
Journal:  World J Surg       Date:  1994 Mar-Apr       Impact factor: 3.352

9.  Hypersplenism is related to age of onset of liver disease.

Authors:  P A McCormick; S Walker; R Benepal
Journal:  Ir J Med Sci       Date:  2007-10-18       Impact factor: 1.568

Review 10.  Parasitic infections of the gastrointestinal tract.

Authors:  C M Noyer; L J Brandt
Journal:  Curr Gastroenterol Rep       Date:  1999-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.